207 related articles for article (PubMed ID: 36314103)
21. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
Zhou Q; Sparreboom A; Tan EH; Cheung YB; Lee A; Poon D; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2005 Apr; 59(4):415-24. PubMed ID: 15801936
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.
Turiján-Espinoza E; Ruíz-Rodríguez VM; Uresti-Rivera EE; Martínez-Leija E; Zermeño-Nava JJ; Guel-Pañola A; Romano-Moreno S; Vargas-Morales JM; Portales-Pérez DP
Cancer Chemother Pharmacol; 2021 Jun; 87(6):843-853. PubMed ID: 33740100
[TBL] [Abstract][Full Text] [Related]
24. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
Daood M; Tsai C; Ahdab-Barmada M; Watchko JF
Neuropediatrics; 2008 Aug; 39(4):211-8. PubMed ID: 19165709
[TBL] [Abstract][Full Text] [Related]
25. Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Kim SH; Kim MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY; Ling H; Lee GW
Am J Clin Oncol; 2015 Jun; 38(3):294-9. PubMed ID: 23689644
[TBL] [Abstract][Full Text] [Related]
26. Karanjin interferes with ABCB1, ABCC1, and ABCG2.
Michaelis M; Rothweiler F; Nerreter T; Sharifi M; Ghafourian T; Cinatl J
J Pharm Pharm Sci; 2014; 17(1):92-105. PubMed ID: 24735762
[TBL] [Abstract][Full Text] [Related]
27. ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling.
Vesel M; Rapp J; Feller D; Kiss E; Jaromi L; Meggyes M; Miskei G; Duga B; Smuk G; Laszlo T; Karner I; Pongracz JE
Respir Res; 2017 Mar; 18(1):52. PubMed ID: 28340578
[TBL] [Abstract][Full Text] [Related]
28. Genetic Variants in the
Morau MV; Seguin CS; Visacri MB; Pincinato EC; Moriel P
Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790220
[TBL] [Abstract][Full Text] [Related]
29. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.
Hill CR; Jamieson D; Thomas HD; Brown CD; Boddy AV; Veal GJ
Biochem Pharmacol; 2013 Jan; 85(1):29-37. PubMed ID: 23063411
[TBL] [Abstract][Full Text] [Related]
30. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
Campa D; Müller P; Edler L; Knoefel L; Barale R; Heussel CP; Thomas M; Canzian F; Risch A
Int J Cancer; 2012 Dec; 131(12):2920-8. PubMed ID: 22473764
[TBL] [Abstract][Full Text] [Related]
32. Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response.
Wada M
Cancer Lett; 2006 Mar; 234(1):40-50. PubMed ID: 16377077
[TBL] [Abstract][Full Text] [Related]
33. Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export.
Wang H; Jin G; Wang H; Liu G; Qian J; Jin L; Wei Q; Shen H; Huang W; Lu D
Cancer; 2009 Feb; 115(3):595-607. PubMed ID: 19107762
[TBL] [Abstract][Full Text] [Related]
34. Expression of ABCB1, ABCC1 and 3 and ABCG2 in glioblastoma and their relevance in relation to clinical survival surrogates.
Roy LO; Lemelin M; Blanchette M; Poirier MB; Aldakhil S; Fortin D
J Neurooncol; 2022 Dec; 160(3):601-609. PubMed ID: 36342588
[TBL] [Abstract][Full Text] [Related]
35. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition.
Haufroid V
Curr Drug Targets; 2011 May; 12(5):631-46. PubMed ID: 21039333
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study.
Cusato J; De Nicolò A; Boglione L; Favata F; Ariaudo A; Mornese Pinna S; Carcieri C; Guido F; Avataneo V; Cariti G; Di Perri G; D'Avolio A
J Antimicrob Chemother; 2018 Jun; 73(6):1659-1664. PubMed ID: 29509884
[TBL] [Abstract][Full Text] [Related]
37. Influence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury.
Cousar JL; Conley YP; Willyerd FA; Sarnaik AA; Puccio AM; Empey PE; Kochanek PM; Bell MJ; Okonkwo DO; Clark RS
Neurocrit Care; 2013 Oct; 19(2):192-8. PubMed ID: 23896815
[TBL] [Abstract][Full Text] [Related]
38. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
Nedeljković M; Tanić N; Prvanović M; Milovanović Z; Tanić N
Breast Cancer; 2021 May; 28(3):727-736. PubMed ID: 33420675
[TBL] [Abstract][Full Text] [Related]
39. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
40. Effects of
Maeda A; Ando H; Irie K; Hashimoto N; Morishige JI; Fukushima S; Ebi H; Uchida K; Iwata H; Sawaki M
Anticancer Res; 2023 Mar; 43(3):1283-1289. PubMed ID: 36854511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]